These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30311534)

  • 1. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
    Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
    Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
    Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothyroid ataxia complicating monoclonal antibody therapy.
    Badran A; Moran C; Coles AJ
    Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 9. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 11. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
    Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
    Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB; Robertson S; Philpott J
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract]   [Full Text] [Related]  

  • 13. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH; Tetzlaff MT; Nelson K; Amaria R; Patel S; Aung PP; Nagarajan P; Torres-Cabala CA; Diab A; Prieto VG; Curry JL
    Int J Dermatol; 2019 Sep; 58(9):1045-1052. PubMed ID: 29152725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
    Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
    Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.